Further, since cDC2-primed CD4+ T cells can improve the magnitude and quality of CD8+ T cells64, the increase in activated cDC2s upon NDV-Flt3L ISV could also benefit anti-tumor immunity. The gene discussed is CD4; the disease is neoplasm.